Literature DB >> 15013721

COX-2: a target for prevention and treatment of esophageal cancer.

Nasser Altorki1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15013721     DOI: 10.1016/j.jss.2003.12.005

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


× No keyword cloud information.
  5 in total

1.  Association between COX-2 polymorphisms and non-small cell lung cancer susceptibility.

Authors:  Tiancheng Zhang; Jing Li; Tian Xia; Nan Zhang; Yaozhou Zhang; Jian Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial.

Authors:  Nasser K Altorki; Paul Christos; Jeff L Port; Paul C Lee; Farooq Mirza; Cathy Spinelli; Roger Keresztes; Debra Beneck; Subroto Paul; Brendon M Stiles; Yuwei Zhang; David S Schrump
Journal:  J Thorac Oncol       Date:  2011-06       Impact factor: 15.609

3.  COX-2 mRNA expression is significantly increased in acid-exposed compared to nonexposed squamous epithelium in gastroesophageal reflux disease.

Authors:  Georg Lurje; Daniel Vallbohmer; Peter H Collet; Huan Xi; Stephan E Baldus; Jan Brabender; Ralf Metzger; Michaela Heitmann; Susanne Neiss; Ute Drebber; Arnulf H Holscher; Paul M Schneider
Journal:  J Gastrointest Surg       Date:  2007-07-10       Impact factor: 3.452

Review 4.  New insights into the functions of Cox-2 in skin and esophageal malignancies.

Authors:  Hyeongsun Moon; Andrew C White; Alexander D Borowsky
Journal:  Exp Mol Med       Date:  2020-04-01       Impact factor: 8.718

5.  A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas.

Authors:  Aafke Creemers; Eva A Ebbing; Thomas C Pelgrim; Sjoerd M Lagarde; Faridi S van Etten-Jamaludin; Mark I van Berge Henegouwen; Maarten C C M Hulshof; Kausilia K Krishnadath; Sybren L Meijer; Maarten F Bijlsma; Martijn G H van Oijen; Hanneke W M van Laarhoven
Journal:  Sci Rep       Date:  2018-09-05       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.